Lv4
462 积分 2022-11-04 加入
Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small cell lung cancer
2天前
已完结
Cross-priming underlies the efficacy of antibody–drug conjugates and immunotherapy combinations
5天前
已完结
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
6天前
已关闭
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
6天前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR-Mutated Advanced NSCLC
6天前
已完结
Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study
7天前
已完结
Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer
7天前
已完结
The next generation of antibody-drug conjugates
7天前
已完结
A modular framework for antibody-drug conjugate biomarkers
8天前
已完结
Antibody-drug conjugate design and mechanisms of action for cancer treatment: state of the art and beyond
2个月前
已完结
皖公网安备34019202002308
